Prostate Cancer

>

Latest News

No dose-limiting toxicities or unexpected adverse effects occurred with carotuximab/apalutamide in metastatic castration-resistant prostate cancer.
Carotuximab/Apalutamide Shows Tolerability in Metastatic CRPC

July 16th 2025

No dose-limiting toxicities or unexpected adverse effects occurred with carotuximab/apalutamide in metastatic castration-resistant prostate cancer.

More detailed overall survival results from the phase 3 EMBARK trial for patients with nmHSPC will be shared at an upcoming medical conference.
Enzalutamide Prolongs Survival in nmHSPC With Biochemical Recurrence

July 11th 2025

Discover the latest advancements in metastatic castration-resistant prostate cancer care, including personalized treatment strategies and emerging therapies.
3 Things You Should Know About Advancing mCRPC Care: Targeted Sequencing, Epigenetics, and Emerging Strategies

July 1st 2025

Gedatolisib showed promising ORRs when given in combination with darolutamide and trastuzumab biosimilar in mCPRC and mBC, respectively.
Early Efficacy Seen With Gedatolisib-Based Therapies in Prostate/Breast Cancers

June 30th 2025

225Ac-LNC1011 targeted α therapy elicited an ORR of 50.0% in patients with PSMA-positive prostate cancer in a phase 1 trial.
Novel Targeted Therapy Shows Promise in PSMA-Positive Prostate Cancer

June 24th 2025

More News